BLCO Stock Forecast & Price Target

Bausch & Lomb has demonstrated strong revenue growth across all three segments in the third quarter of 2025, with Vision Care, Surgical, and Pharmaceutical revenues increasing by 8%, 4%, and 8% year-over-year, respectively, contributing to a total revenue of $1.28 billion. The company has regained momentum in premium intraocular lenses (IOLs), evidenced by growth in its enVista and LUX platforms, while MIEBO has shown remarkable performance with a 110% year-over-year increase in prescriptions. Additionally, despite reporting a net loss of $28 million for the quarter, the loss was significantly lower than expected, reinforcing confidence in the company's financial trajectory.

Bausch & Lomb faces significant challenges maintaining its leadership position in a highly competitive ophthalmology market, compounded by a limited product pipeline and insufficient investments made while part of Bausch Health. Macroeconomic uncertainties, particularly regarding elective procedures and consumer spending, could adversely affect sales in key segments such as cataract surgeries and contact lenses. Additionally, high levels of leverage from the Novartis acquisition and ongoing uncertainties related to the complete separation from Bausch Health may hinder long-term growth prospects and contribute to stock price volatility.